Last reviewed 2026-04-23 · How we verify

HS-25

HS-25 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).

HS-25 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.

At a glance

Mechanism of action

By inhibiting SGLT2, HS-25 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.

Approved indications

• Treatment of type 2 diabetes

Common side effects

• Increased risk of genital mycotic infections
• Increased risk of urinary tract infections

Key clinical trials

• Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia (PHASE3)
• Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases (PHASE3)
• Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia (PHASE3)
• A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HS-25 CI brief — competitive landscape report
• HS-25 updates RSS · CI watch RSS
• Zhejiang Hisun Pharmaceutical Co. Ltd. portfolio CI